Arcutis Biotherapeutics, Inc.
ARQTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company carries a $3.56B market cap, placing it firmly in the mid-cap category. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Market Cap
$3.56B
Beta
1.48
P/E (TTM)
—
P/E (Fwd)
25.14
EPS (TTM)
$-0.02
EPS (Fwd)
$1.13
ROE
-1.4%
ROA
0.5%
Cash
$224.0M
Total Debt
$114.7M
Free CF
$3.5M
52W Change
94.2%
Annual Financials
Cash vs Debt
Arcutis Biotherapeutics, Inc. holds $224.0M in cash against $114.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $3.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -1.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 0.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $3.7M (2022) to $376.1M (2025), reflecting a 10103% increase over the period.
As with any equity investment, ARQT carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing ARQT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.